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ABSTRACT
Objective: To determine the prevalence of cutaneous anergy in pregnant and nonpregnant women
who are seropositive for human immunodeficiency virus.
Methods and materials: The medical records of 159 women seropositive for human immunode-
ficienc virus were reviewed. Demographic characteristics and tuberculin skin test results were
abstracted from the chart. Tuberculin skin testing was performed by the Mantoux method (5
tuberculin units of purified protein derivative injected intradermally). Anergy testing was per-
formed using any two of the three following antigens; tetanus toxoid, mumps, or Candida skin test
antigen. A positive tuberculin test was defined as induration of5 mm or more, and a positive test for
the other antigens was defined as any amount of induration over the skin test area. Anergy was
defined as any amount of induration to the other antigens. A CD4+T lymphocyte count was
obtained at the time of skin testing. Continuous variables were analyzed using the Mann Whit-
neymU test. Categorical data were analyzed with the chi-square or Fisher’s exact test as appro-
priate. A two-tailed P value < 0.05 was considered significant.
Results: There were 102 nonpregnant and 57 pregnant women who returned to have their skin
test results read. There was no significant difference in the prevalence of positive, negative or
anergic skin test results between groups. The CD4+T lymphocyte count (mean standard devia-
tion) in patients with anergic results was similar between pregnant (375 256/mm3) and nonpreg-
nant (358 + 305/mm3) women (P 0.64).
Conclusion: The prevalence of cutaneous anergy is similar among pregnant and nonpregnant
women seropositive for human immunodeficiency virus. Infect. Dis. Obstet. Gynecol. 6:13-17,
1998. (C) 1998 Wiley-Liss, Inc.
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resurgence in the prevalence of tuberculosis
(TB) has been observed since 1985 that has
largely been attributed to the increasing prevalence
of human immunodeficiency virus (HIV) infec-
tion. 1,2 From 1985 through 1992, the number of
reported TB cases increased 44% among persons
aged 25-44 years, which was twice the rate ob-
served overall in the United States during the same
period.
3 These results indicated that TB may be an
increasing problem among reproductive-aged
women.
Presently in the United States, women account
for the most rapid increase in the number of cases
of HIV.4 These women are largely indigent minor-
ity women from large urban areas who are also at
increased risk for TB. Indeed, a resurgence of ac-
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tive tuberculosis has been observed among repro-
ductive-age women in endemic areas,s
Skin testing along with an anergy panel has
been routinely used to screen for TB in HIV-
positive patients. Cutaneous anergy is a risk factor
for the development of TB and is more prevalent
among HIV-seropositive than seronegative pa-
tients.6-s Anergy also appears to increase as im-
mune function declines.8-11
The pregnancy state by itself has not been used
to modify the criterion for defining a positive tu-
berculin skin test. However, the relationship be-
tween anergy and pregnancy is not well under-
stood. Since CD4+T lymphocytes have been re-
ported to decline steadily during pregnancy by
some authors, it is theoretically possible that an-
ergy would be more common in pregnant than non-
pregnant women, lz,13 Our objective is to determine
the prevalence of cutaneous anergy among HIV-
seropositive pregnant and nonpregnant women.
METHODS AND MATERIALS
The medical records of a cohort of HIV-positive
women monitored at the University of Texas
Women’s Immunology Center, Houston, Texas,
were reviewed between January 1, 1996, and Janu-
ary 31, 1997. All patients undergoing tuberculin
skin testing had demographic characteristics, Cen-
ters for Disease Control (CDC) classification, and
skin test results abstracted from the chart.
Skin test administration and reading were per-
formed by trained staff. Tuberculin skin testing
was performed by the Mantoux method; 0.1 ml of
purified protein derivative (PPD) (tuberculin units
per 0.1 ml Tubersol, Connaught Laboratories, Inc.,
Swiftwater, PA) was injected intradermally into the
volar aspect of the right forearm. Anergy testing
was performed using any two of the three following
antigens: 0.1 ml of tetanus toxoid solution (5 limit
of flocculation units per 0.5 ml of purified fluid
[Ultrafined, Wyeth-Ayerst Laboratories, Philadel-
phia, PAl), 0.1 ml of mumps skin test antigen (40
complement-fixing units per 1.0 ml [Connaught
Laboratories, Inc.]), or 0.1 ml of Candida albicans
skin test antigen (ALK Laboratories, Wallingford,
CT) administered similarly in separate sites on the
volar aspect of the left forearm.
Readings were performed 48-72 hours following
administration of the skin tests. The size of indu-
ration was measured with a flexible ruler. Erythe-
TABLE I. Demographic data
Nonpregnant
(n 102)
Pregnant
(n 57)
Age (years) 28.2 + 7.8 22.9 + 5.3
Parity 2.1+ 1.7 1.3 + 1.4
Ethnicity
Caucasian 7 (6.8%) 8 (14%)
African American 82 (80.4%) 42 (73.6%)
Hispanic 13 (12.8%) 6 (10.5%)
Other 0 (I.9%)
P < 0.005
bData are expressed as the mean + standard deviation.
CNumber (%)
ma alone did not constitute a positive response. A
positive tuberculin test was defined as induration
of 5 mm or more, and a positive anergy test for the
other antigens was defined as any amount of indu-
ration over the skin test area.4 Anergy was defined
as any amount of induration to the other antigens.
Patients were excluded from skin testing if
there was a history of tuberculin reaction of 10 mm
or more verified in the patient’s medical record, a
history of a positive tuberculin reaction with treat-
ment for TB infection or disease verified in the
medical record, or placement of a tuberculin skin
test seven days or less before the visit.
A blood sample for evaluation of lymphocyte
subsets was drawn at the time the skin test was
placed. Lymphocyte phenotyping was performed
as lysed anticoagulated whole blood specimens by
dual-color flow cytometry.
Statistical analysis was performed using a com-
puter software package (True Epistat, Richardson,
TX). Continuous data were analyzed using the
Mann Whitney U-test. Categorical data were ana-
lyzed with the chi-square or Fishers’ exact test as
appropriate. A two-tailed P value <0.05 was consid-
ered statistically significant.
RESULTS
During the study period, 139 nonpregnant and 73
pregnant women received tuberculin skin testing.
Thirty seven nonpregnant (26.6%) and 16 pregnant
(22%) women did not return to have their results
read. This left 159 women (102 nonpregnant and
57 pregnant women) for review.
Demographic data are shown in Table 1. Non-
pregnant women were significantly older and of
greater parity than pregnant women in this cohort,
although this finding is unlikely to be clinically
significant.
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TABLE 2. Mantoux skin test results
Nonpregnant Pregnant
(n 102) (n 57)
Positive 13 (12.7%) 5 (8.7%)
Negative 62 (60.7%) 37 (64.9%)
Anergic 27 (26.6%) 15 (26.4%)
ap was not significant.
Eighteen (11.3%) of 159 women had positive
tuberculin skin test results. Of these eighteen
women with positive skin tests, two had positive
chest X-rays. One patient had active TB, while the
other had a right lower lobe pneumonia. Neither
patient was pregnant. Both patients were treated
with standard therapy. Forty-two (26.4%) of 159
women had anergic skin test results. All of these
women had negative chest X-rays.
The CD4+T lymphocyte count (mean __+ stan-
dard deviation) was similar between pregnant (466
+_ 258/mm3) and nonpregnant women (456 _+ 279/
mm3, P 0.76). Tuberculin skin test results in
pregnant and nonpregnant women are shown in
Table 2. There was no significant difference in the
prevalence of positive, negative, or anergic results
between groups. Table 3 shows the CD4+ lympho-
cyte counts in patients with anergic skin test re-
suits. The CD4+T lymphocyte counts ranged be-
tween 8 and 1500 cells/mm among nonpregnant
women and 27 to 760 cells/mm in pregnant
women. However, there was no significant differ-
ence in the absolute CD4 count between groups
using the current CDC classification. The CD4
count (mean _+ standard deviation) in patients with
anergic results was similar between pregnant (375 _+
256/mm) and nonpregnant (358 _
305/mm)
women (P 0.64).
DISCUSSION
The occurrence of tuberculosis among persons
with HIV infection has prompted the development
of guidelines for screening of TB. These guide-
lines include the recommendation that all HIV-
infected persons receive a PPD tuberculin skin test
(Mantoux test). Because of recent findings of an-
ergy among asymptomatic persons with HIV, per-
sons with HIV infection should also be evaluated
for delayed-type hypersensitivity anergy in con-
junction with PPD testing, ls These recommenda-
tions also include consideration of preventative
therapy with isoniazid for anergic persons who are
TABLE 3. CD4+T-lymphocyte counts in patients
with anergic skin test results
Nonpregnant Pregnant
(n 27) (n 15)
>500/mm 5 (I 8.5%) 4 (26.7%)
200-499/mm 14 (51.8%) 5 (33.3%)
<200/mm 8 (29.7%) 6 (40%)
aP was not significant.
known contacts of infectious tuberculosis patients
and those from groups in which the prevalence of
tuberculosis is >10%. ls Studies of parenteral drug
users and homosexual men have observed an el-
evated risk for the development of active TB
among anergic HIV-infected patients (2-12% per
year). 16’17 This risk substantially exceeds the esti-
mated 10% lifetime risk for development of active
TB in persons with a positive tuberculin test result
and an intact immune system.
These recommendations also would apply to
pregnant women, although historically most obste-
tricians have deferred chemoprophylaxis until after
delivery. This is primarily due to reports of an in-
creased risk of hepatotoxicity from isoniazid in
pregnant women with anergy. 18 Despite the risk of
isoniazid hepatitis, some experts recommend that
chemophaphylaxis be strongly considered after the
first trimester for HIV-infected pregnant women
with anergy.3
Although TB skin testing along with an anergy
panel has been widely used, little information ex-
ists as to the prevalence of anergy among women,
specifically during pregnancy. Studies have dem-
onstrated that CD4+T lymphocytes decline during
normal pregnancy by approximately 100 cells/
mm3. lz,3 Others have reported no difference in T
lymphocyte subsets between HIV-infected and
noninfected women. 19 Since anergy has been
shown to be indirectly proportional to the CD4+T
lymphocyte count, pregnant women would theo-
retically be more likely to have anergic test re-
sults.8,s This would potentially expose a greater
proportion of pregnant women to chemoprophy-
laxis then nonpregnant women.
The overall prevalence of anergy in our study
(26.4%) is lower than other large cohorts of HIV-
infected persons. These studies primarily consisted
of male homosexuals or parenteral drug users in
which the incidence of anergy ranged from 36 to
63%.7,8,1,e Unexpectedly, we did not observe any
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difference in the prevalence of anergy between
pregnant and nonpregnant women. Although the
CD4+T lymphocyte counts were on average 100
cells/mm
3 lower in the women with anergy, there
was no significant difference in the CD4 count be-
tween pregnant and nonpregnant women. Our re-
sults differ from those of Mofenson’s and cowork-
ers, in which anergy was more common in nonpreg-
nant (38/78, 49%) than pregnant (14/46, 30%)
women. 13 These results may be explained by the
lower CD4 count seen in the nonpregnant patients
in their cohort.
Previous studiess,l,s have shown an inverse re-
lationship in the prevalence of anergy as compared
with the CD4 count. The prevalence of anergy
ranges from 72 to 80% in patients with fewer than
200 CD4 cells/mm. 7,1s This is in contrast to our
results in which 14/42 (33%) ofwomen with anergic
results had a CD4 count less than 200 cells/mm3.
The wide range of CD4+T lymphocyte counts in
our population confirms other investigators, obser-
vations that an absolute CD4+ count does not re-
liably predict anergic test results, is
Although current CDC guidelines recommend
consideration of chemoprophylaxis in anergic pa-
tients, others question the value and reliability of
testing for anergy,e,zl This is because no gold stan-
dard is available to define the anergic state, and the
performance of tests for detecting anergy cannot be
evaluated in a conventional manner. Although ob-
servational data supports the conclusion that cer-
tain HIV-infected people with anergy are at high
risk for active tuberculosis, until recently no data
existed as to the benefit of providing chemopro-
phylaxis to this population. In a recent randomized
double-blind controlled trial, Gordin et al. did not
show a reduction in the incidence of tuberculosis in
HIV-infected patients with anergy who received
chemoprophylaxis with isoniazid,zz Although the
results of Gordin’s study do not support the use of
chemoprophylaxis for anergic HIV-infected pa-
tients, consideration must be given to the risk of
hematogenous transmission of TB to the fetus.
In summary, despite the observed decrease in
the CD4+T lymphocyte counts, pregnancy did not
alter the prevalence of cutaneous anergy in our
population of HIV-infected women. Questions re-
garding the reliability of anergy testing and the
apparent lack of benefit of chemoprophylaxis for
these patients should prompt reconsideration of
routine anergy testing of the HIV-infected patient.
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